Navigation Links
Judge Nullifies Verdict in Diabetes Drug Case
Date:5/1/2013

oking statements include statements regarding Takeda's plans, outlook, strategies, results for the future, and other statements that are not descriptions of historical facts. Forward-looking statements may be identified by the use of forward-looking words such as "may," "believe," "will," "expect," "project," "estimate," "should," "anticipate," "plan," "assume," "continue," "seek," "pro forma," "potential," "target," "forecast," "guidance," "outlook" or "intend" or other similar words or expressions of the negative thereof. Forward-looking statements are based on estimates and assumptions made by management that are believed to be reasonable, though they are inherently uncertain and difficult to predict. Investors are cautioned not to unduly rely on such forward-looking statements.

Forward-looking statements involve risks and uncertainties that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements. Some of these risks and uncertainties include, but are not limited to, (1) the economic circumstances surrounding Takeda's business, including general economic conditions in Japan, the United States and worldwide; (2) competitive pressures and developments; (3) applicable laws and regulations; (4) the success or failure of product development programs; (5) actions of regulatory authorities and the timing thereof; (6) changes in exchange rates; (7) claims or concerns regarding the safety or efficacy of marketed products or product candidates in development; and (8) integration activities with acquired companies.

The forward-looking statements contained in this press release speak only as of the date of this press release, and Takeda undertakes no obligation to revise or update any forward-looking statements to reflect new information, future events or circumstances after the date of the forward-looking statement. If Taked
'/>"/>

SOURCE Takeda Pharmaceuticals U.S.A., Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. AUL says New York Judges Ruling Allows Big Abortion to Gamble with Young Girls Health
2. Arizona Judge Rules That Arizona Medical Marijuana Law is Constitutional
3. Judge Upholds $3.3 Million Judgment In Favor of Fox Insurance Company Against Former Pharmacy Benefit Manager
4. Takeda Responds to Verdict in Diabetes Drug Case
5. DePuy Settlement News: J&J Wins Major Verdict In Illinois Trial
6. Volcano Announces Previous St. Jude Medical Products Infringe Volcano Patent and Jury Verdicts in Patent Trials with St. Jude Medical
7. Federal Appeals Court Upholds Fraud Verdict Against Cornell University Medical School For Misuse Of NIH Aids Funding
8. Hologic Announces Verdict In Patent Infringement Suit
9. Coloplast Wins Patent Infringement Verdict Against Generic Medical Devices, Inc.
10. $78.5 Million Jury Verdict In Philadelphia Birth Injury Case
11. The Importance of Emergency Preparedness: Lilly Diabetes and the American College of Endocrinology (ACE) Help Prep People with Diabetes for Emergencies - Big or Small
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... Inc. (Nasdaq: SMLR ), a company that provides ... groups, today reported financial results for the second quarter ... second quarter of 2015, Semler reported continued progress with ... quarter revenue growth of 8%, and quarter over quarter ... 18%," said Doug Murphy-Chutorian, M.D., chief executive officer of ...
(Date:7/31/2015)... WOODCLIFF LAKE, N.J. and SAN ... announced today that its parent company Eisai Co., Ltd. ... Haruo Naito , "Eisai") and Halozyme Therapeutics, Inc. ... and CEO: Dr. Helen Torley , "NASDAQ: HALO") ... eribulin mesylate (brand name: Halaven ® , "eribulin") in ...
(Date:7/31/2015)... July 31, 2015  Xencor, Inc. (NASDAQ: XNCR ... for the treatment of autoimmune diseases, asthma and allergic ... Yujiro S. Hata to its board of directors. ... and corporate development is a tremendous asset to our ... chief executive officer of Xencor. "Xencor faces a range ...
Breaking Medicine Technology:Semler Reports Second Quarter 2015 Financial Results 2Semler Reports Second Quarter 2015 Financial Results 3Semler Reports Second Quarter 2015 Financial Results 4Semler Reports Second Quarter 2015 Financial Results 5Semler Reports Second Quarter 2015 Financial Results 6Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6Xencor Appoints Yujiro S. Hata to Board of Directors 2Xencor Appoints Yujiro S. Hata to Board of Directors 3
... N.J., Dec. 8, 2011  At the Radiological Society ... announced its plans to enter the radiology display ... in display technology to bring a comprehensive line ... "Sony has set the standard for ...
... Dec. 8, 2011 Ecology Coatings, Inc. ... development of nanotechnology-enabled, ultraviolet-curable advanced coatings, today announced ... the rigorous requirements of the healthcare industry.  The ... patient wristband and is benzophenone free—a request that ...
Cached Medicine Technology:Ecology Coatings Develops UV-Curable Coatings for Medical Wristbands 2Ecology Coatings Develops UV-Curable Coatings for Medical Wristbands 3
(Date:7/31/2015)... Orlando, FL (PRWEB) , ... July 31, 2015 , ... ... visiting the United States for temporary work, study or family visit for the past ... in their 80s and 90s are able to travel and spend time with their ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... apnea (OSA) and the growing number of individuals who remain undiagnosed, treatment options ... continue to shy away from traditional CPAP therapy due to its overall lack ...
(Date:7/30/2015)... ... ... The Venetian on Grace Bay in the Turks & Caicos Islands is pleased to announce ... 40% on their stay while enjoying some of the most beautiful ocean views in the ... a chance to reconnect with loved ones and rediscover one's best self. The sea ...
(Date:7/30/2015)... ... July 30, 2015 , ... As more hospitals across the country see the ... a serious challenge. Because of growing competition, it is more important than ever ... , The team at Wound Care Advantage has found that while ...
(Date:7/30/2015)... , ... July 30, 2015 , ... The connection between a healthy head of hair ... The loss of a full head of hair can have a devastating impact on the ... is perceived in the work place, the consequences of hair loss are not to be ...
Breaking Medicine News(10 mins):Health News:India Network Visitor Health Insurance Announces Completion of Food Grains Distribution to Godavari Pushkaram Visitors, Andhra Pradesh, India 2Health News:India Network Visitor Health Insurance Announces Completion of Food Grains Distribution to Godavari Pushkaram Visitors, Andhra Pradesh, India 3Health News:Oravan Sleep Apnea Device Gains Traction in Sleep Industry 2Health News:The Venetian on Grace Bay in Turks & Caicos Islands Offers 40% Savings This Fall. 2Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 2Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 3Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 4Health News:New Study Shows the Link between Hair Restoration and Healthy Self-Image 2
... Reporter , WEDNESDAY, Feb. 29 (HealthDay News) -- Two ... people with the rare bone marrow disorder called myelofibrosis. ... brand name Jakafi, won,t cure myelofibrosis, it can help ease ... to the studies. "This is probably the most ...
... report published this week in the New England Journal ... melanoma patients with a specific genetic mutation benefit from the ... to 15.9 months. In patients who responded, the drug stopped ... patients with a BRAF V600 mutation, this drug is a ...
... of Traumatic Brain Injury Research at Kessler Foundation, is an ... on March 6, 2012, in Washington, DC. Dr. Grafman ... brain injury. A well known expert, he will focus on ... injury and genetic polymorphisms on social abilities and quality of ...
... Colin Farrelly wants to see more research into remarkable ... live 100 years disease-free. He describes the current pathology-based ... biology" and suggest more resources should be focused on ... the question ,what causes disease?, is the most significant ...
... -- Strict enforcement of underage drinking laws reduces the ... new study suggests. State lawmakers have relied heavily on ... of alcohol under the legal age laws -- to control ... on young people aged 15 to 24 from the FBI,s ...
... HealthDay Reporter , WEDNESDAY, Feb. 29 (HealthDay News) -- ... FDA mandate that would have forced tobacco companies to ... The proposed requirement from the U.S. Food and Drug ... would have emblazoned cigarette packaging with images of people ...
Cached Medicine News:Health News:New Drug May Help Fight Rare Bone Marrow Disorder 2Health News:New Drug May Help Fight Rare Bone Marrow Disorder 3Health News:Kessler Foundation neuroscientist addresses 2nd Annual TBI Conference in Washington DC 2Health News:Strict Underage Drinking Laws May Deter Delinquency in Teens 2Health News:Judge Blocks Plan for Graphic Cigarette Warnings 2
... basic laboratory system for pH and temperature ... obtained when used with a temperature probe ... and easy one and two-point calibration with ... (pH 1.68, 4.00, 7.00, 10.01 and 12.45) ...
... Detectors provide unmatched value and flexibility ... automation needs. Capable of performing fluorescence, ... same instrument, the DTX Series can ... be integrated seamlessly with Beckman Coulters ...
... Designed for High Throughput Screening ... of assays into HTS by sharing ... performance of Analyst AD, fluorescence intensity, ... Optimized for seamless integration into ...
... features for assay development and basic ... Reduces the inevitable transfer time required ... developed to meet the challenges of ... unparalleled detection performance for Fluorescence Intensity, ...
Medicine Products: